Predict your next investment

Venture Capital
solcap.com

See what CB Insights has to offer

Investments

70

Portfolio Exits

19

Funds

2

About Solstice Capital

The first Solstice fund, was formed in 1995, and invested in 21 portfolio companies. In July 2001, Solstice Capital formed Solstice Capital II Limited Partnership, a $62 million early-stage venture fund, which has invested in 24 companies. Solstice Capital currently has $85 million of capital under management.Solstice is committed to investing 50% of its capital in information technology and 50% in the following socially responsive investment categories: * Alternative Energy * The Environment * Life Sciences * Education

Solstice Capital Headquarter Location

15 Broad Street Third Floor

Boston, Massachusetts, 02109,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Solstice Capital News

Splash Pharmaceuticals Announces Financing to Advance Ovarian Cancer Clinical Trial

May 22, 2018

Splash Pharmaceuticals, Inc. (“Splash”), a private biopharmaceutical company that develops novel cancer therapies, announced completion of a financing round to support the ongoing clinical trial of SPL-108. The round was oversubscribed and was led by existing investors Hamilton BioVentures (“Hamilton”) and Solstice Capital. The proceeds will support Splash’s clinical trial in platinum-resistant ovarian cancer patients. Splash is developing a pipeline of novel therapeutics that target CD44 with the goal to achieve dramatic and durable responses in cancer patients. The first of these therapies, SPL-108, has demonstrated significant activity in animal models including ovarian, breast, endometrial, prostate, liver and brain cancers. SPL-108 has also demonstrated activity in multiple Phase I and II clinical trials in gynecological cancers with an excellent safety profile. Splash believes that combining SPL-108 with other therapies will provide even greater activity which is the basis for the current clinical trial. “We are very pleased to close this financing round and are particularly gratified by the strong support from our existing investors who know the story best,” said Dr. David Nelson, President and CEO of Splash Pharmaceuticals. “We are excited by the breadth and depth of preclinical and clinical data that we have generated in support of our latest clinical trial in ovarian cancer. SPL-108 holds great promise for many types of cancer and we look forward to testing this clinical hypothesis with our latest trial.” “Hamilton is excited to participate in this financing round,” said Dr. Kerry Dance, Chairman of Hamilton BioVentures. “The unique mechanism of action of SPL-108 provides a compelling possibility of achieving durable responses, which is something that has remained elusive in many recent breakthrough cancer therapies.” About Splash Pharmaceuticals Splash is a privately held company that is developing novel cancer therapies with a goal to provide dramatic and durable responses in many solid tumors. Splash has developed a pipeline of novel agents that target CD44 with demonstrated anti-angiogenic and anti-metastatic activity as well as synergistic cytotoxicity with other chemotherapy agents. Splash is actively seeking Pharma partners to accelerate its novel clinical programs. For more information, visit www.splashpharma.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20180521006108/en/ Splash Pharmaceuticals

Solstice Capital Investments

70 Investments

Solstice Capital has made 70 investments. Their latest investment was in RxActuator as part of their Unattributed VC on November 11, 2020.

CBI Logo

Solstice Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

11/6/2020

Unattributed VC

RxActuator

$0.4M

Yes

4

7/16/2019

Unattributed VC - III

Post.Bid.Ship

$1.72M

Yes

1

5/22/2018

Series D

Splash Pharmaceuticals

Yes

1

10/30/2014

Series B - II

Subscribe to see more

$99M

Subscribe to see more

10

10/14/2014

Series F

Subscribe to see more

$99M

Subscribe to see more

10

Date

11/6/2020

7/16/2019

5/22/2018

10/30/2014

10/14/2014

Round

Unattributed VC

Unattributed VC - III

Series D

Series B - II

Series F

Company

RxActuator

Post.Bid.Ship

Splash Pharmaceuticals

Subscribe to see more

Subscribe to see more

Amount

$0.4M

$1.72M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

1

1

10

10

Solstice Capital Portfolio Exits

19 Portfolio Exits

Solstice Capital has 19 portfolio exits. Their latest portfolio exit was SynCardia Systems on July 06, 2016.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/6/2016

Asset Sale

$99M

2

6/29/2015

Acquired

$99M

1

5/6/2015

IPO

$99M

Public

1

2/10/2014

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

9/18/2013

Acq - Fin

Subscribe to see more

$99M

Subscribe to see more

10

Date

7/6/2016

6/29/2015

5/6/2015

2/10/2014

9/18/2013

Exit

Asset Sale

Acquired

IPO

Acquired

Acq - Fin

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

2

1

1

10

10

Solstice Capital Fund History

2 Fund Histories

Solstice Capital has 2 funds, including Solstice Capital II LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/16/2001

Solstice Capital II LP

Early-Stage Venture Capital

Closed

$62M

1

10/6/1995

Solstice Capital LP

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

11/16/2001

10/6/1995

Fund

Solstice Capital II LP

Solstice Capital LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Closed

Subscribe to see more

Amount

$62M

$99M

Sources

1

10

Solstice Capital Team

4 Team Members

Solstice Capital has 4 team members, including current Managing Partner, Harry George.

Name

Work History

Title

Status

Dan Matthies CFA CAIA

Founder

Current

Harry George

Managing Partner

Current

Henry W. Newman

General Partner

Current

Stephen E Tomasula

Chief Financial Officer

Former

Name

Dan Matthies CFA CAIA

Harry George

Henry W. Newman

Stephen E Tomasula

Work History

Title

Founder

Managing Partner

General Partner

Chief Financial Officer

Status

Current

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.